力扑素肺癌(王教授).pptx

紫杉醇脂质体(力扑素)联合铂类治疗伴有区域淋巴结转移的非小细胞肺癌 紫杉醇在晚期NSCLC治疗中的地位如何？ 晚期NSCLC治疗的历史回顾 2000 *Label does not include NSCLC-specific indication First-line Second-lineThird-line Not approved 1970 1980 1990 Medianoverallsurvival,months 12+ ~8–10 ~6 ~2–4 Best supportive care Single-agent platinum Doublets EGFR-TKI Bevacizumab + 化疗 Cisplatin*1978 Carboplatin*1989 ErlotinibPemetrexed2004 Docetaxel1999 PaclitaxelGemcitabine 1998 Vinorelbine1994 Docetaxel2002 Bevacizumab2006 Gefitinib2003 Standard therapies Food and Drug Administration. At /cder/cancer/druglistframe.htm. Accessed August 28, 2006.; Natio